Spyridoula Vasileiou

Jan 10, 2025 | science.org | Daniel Rabe |Matthew Weller |Bhoktear Khan |Ahmed Gad |Jessica Morris |Lea Godret-Miertschin | +10 more

AbstractChimeric antigen receptor T cells (CART) targeting CD19 through CD28.ζ signaling induce rapid lysis of leukemic blasts, contrasting with persistent tumor control exhibited by 4-1BB.ζ-CART. We reasoned that molecular dynamics at the CART immune synapse (CARIS) could explain differences in their tumor rejection kinetics.

Jan 7, 2025 | digitalcommons.library.tmc.edu | Valentina Hoyos |Spyridoula Vasileiou |Manik Kuvalekar |Ayumi Watanabe

PURPOSE: Adoptively transferred, ex vivo expanded multi-antigen-targeted T cells (multiTAA-T) represent a new, potentially effective, and nontoxic therapeutic approach for patients with breast cancer (BC). In this first-in-human trial, we investigated the safety and clinical effects of administering multiTAA T cells targeting the tumor-expressed antigens, Survivin, NY-ESO-1, MAGE-A4, SSX2, and PRAME, to patients with relapsed/refractory/metastatic BC.